Operative Techniques in Orthopaedics
Volume 19, Issue 2 , Pages 77-87 , April 2009

Bone Graft Substitutes in the Treatment of Distal Radius and Upper Limb Injuries

  • Jeffrey Yao, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jeffrey Yao, MD, Department of Hand and Orthopaedic Surgery, Stanford University School of Medicine, 770 Welch Road, Suite 400, Palo Alto, CA 94304
    • ,
  • Andrew M. Ho, MD, PhD

References 

  1. Urist MR. Bone: Formation by autoinduction. Science. 1965;150:893–899
  2. Ladd AL, Pliam NB. Use of bone-graft substitutes in distal radius fractures. J Am Acad Orthop Surg. 1999;7:279–290
  3. Kang JS, Kim NH. The biomechanical properties of deep freezing and freeze drying bones and their biomechanical changes after in-vivo allograft. Yonsei Med J. 1995;36:332–335
  4. Friedlaender GE, Strong DM, Sell KW. Studies on the antigenicity of bone (I. Freeze-dried and deep-frozen bone allografts in rabbits). J Bone Joint Surg Am. 1976;58:854–858
  5. Russell JL, Block JE. Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: Impact of processing techniques and study methodology. Orthopedics. 1999;22:524–531
  6. Harakas NK. Demineralized bone-matrix-induced osteogenesis. Clin Orthop Relat Res. 1984;188:239–251
  7. Wang JC, Kanim LE, Nagakawa IS, et al. Dose-dependent toxicity of a commercially available demineralized bone matrix material. Spine. 2001;26:1429–1435
  8. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials. 2005;26:5474–5491
  9. Guda T, Appleford M, Oh S, et al. A cellular perspective to bioceramic scaffolds for bone tissue engineering: The state of the art. Curr Top Med Chem. 2008;8:290–299
  10. Werber KD, Brauer RB, Weiss W, et al. Osseous integration of bovine hydroxyapatite ceramic in metaphyseal bone defects of the distal radius. J Hand Surg. 2000;25A:833–841
  11. Martin RB, Chapman MW, Sharkey NA, et al. Bone ingrowth and mechanical properties of coralline hydroxyapatite 1 yr after implantation. Biomaterials. 1993;14:341–348
  12. Norman ME, Elgendy HM, Shors EC, et al. An in-vitro evaluation of coralline porous hydroxyapatite as a scaffold for osteoblast growth. Clin Mater. 1994;17:85–91
  13. Bell WH. Resorption characteristics of bone and bone substitutes. Oral Surg Oral Med Oral Pathol. 1964;17:650–657
  14. Thomas MV, Puleo DA. Calcium sulfate: Properties and clinical applications. J Biomed Mater Res B Appl Biomater. 2009;88:597–610
  15. Nakagawa N, Saegusa Y, Abe S, et al. The effectiveness of RA wrist fusion using Beta-TCP without autogenous iliac bone grafting: A report of four cases. Hand Surg. 2006;11:71–75
  16. Scheer JH, Adolfsson LE. Tricalcium phosphate bone substitute in corrective osteotomy of the distal radius. Injury. 2009;40:262–267
  17. Sanchez-Sotelo J, Munuera L, Madero R. Treatment of fractures of the distal radius with a remodellable bone cement: A prospective, randomised study using Norian SRS. J Bone Joint Surg Br. 2000;82:856–863
  18. Cassidy C, Jupiter JB, Cohen M. Norian SRS cement compared with conventional fixation in distal radial fractures (A randomized study). J Bone Joint Surg Am. 2003;85-A:2127–2137
  19. Dickson KF, Friedman J, Buchholz JG, et al. The use of BoneSource hydroxyapatite cement for traumatic metaphyseal bone void filling. J Trauma. 2002;53:1103–1108
  20. Jeyam M, Andrew JG, Muir LT, et al. Controlled trial of distal radial fractures treated with a resorbable bone mineral substitute. J Hand Surg Br. 2002;27:146–149
  21. McKee MD. Hydroxyapatite cement was not as effective as intrafocal Kirschner-wire fixation for acute fractures of the distal part of the radius. J Bone Joint Surg Am. 2003;85-A:386
  22. Russell TA, Leighton RK Alpha-BSM Tibial Plateau Fracture Study Group. Comparison of autogenous bone graft and endothermic calcium phosphate cement for defect augmentation in tibial plateau fractures (A multicenter, prospective, randomized study). J Bone Joint Surg Am. 2008;90:2057–2061
  23. Cornell CN, Lane JM, Chapman M, et al. Multicenter trial of collagraft as bone graft substitute. J Orthop Trauma. 1991;5:1–8
  24. Leupold JA, Barfield WR, An YH, et al. A comparison of ProOsteon, DBX, and collagraft in a rabbit model. J Biomed Mater Res B Appl Biomater. 2006;79:292–297
  25. Wheeler DL, Eschbach EJ, Hoellrich RG, et al. Assessment of resorbable bioactive material for grafting of critical-size cancellous defects. J Orthop Res. 2000;18:140–148
  26. Kingsley DM. The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994;8:133–146
  27. Dean DB, Watson JT, Moed BR, et al. Role of bone morphogenetic proteins and their antagonists in healing of bone fracture. Front Biosci. 2009;14:2878–2888
  28. Mehta S, Watson JT. Platelet rich concentrate: Basic science and current clinical applications. J Orthop Trauma. 2008;22:432–438
  29. Bielecki T, Gazdzik TS, Szczepanski T. Benefit of percutaneous injection of autologous platelet-leukocyte-rich gel in patients with delayed union and nonunion. Eur Surg Res. 2008;40:289–296
  30. Gandhi A, Doumas C, O'Connor JP, et al. The effects of local platelet rich plasma delivery on diabetic fracture healing. Bone. 2006;38:540–546
  31. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34:1774–1778
  32. Greenwald AS, Boden SD, Goldberg VM. Bone-graft substitutes: Facts, fictions, and applications. J Bone Joint Surg Am. 2001;83-A(suppl 2):98–103
  33. Friedlaender GE, Perry CR, Cole JD. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83-A(suppl 1):S151–S158
  34. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: A long-term (>4 years) pivotal study. Spine. 2008;15:2850–2862
  35. Govender S, Csimma C, Genant HK. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84-A:2123–2134
  36. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial: 2002 Volvo award in clinical studies. Spine. 2002;27:2662–2673
  37. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine. 2006;31:2813–2819
  38. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery. 2008;62(suppl 2):ONS423–ONS431
  39. Tanaka E, Ishino Y, Sasaki A, et al. Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Ann Biomed Eng. 2006;34:717–725
  40. Eckardt H, Ding M, Lind M, et al. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br. 2005;87:1434–1438
  41. Peng H, Usas A, Olshanski A, et al. VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Miner Res. 2005;20:2017–2027
  42. Wang H, Li X, Tomin E, et al. Thrombin peptide (TP508) promotes fracture repair by upregulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res. 2005;23:671–679
  43. Ryaby JT, Sheller MR, Levine BP, et al. Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. J Bone Joint Surg Am. 2006;88(suppl 3):132–139
  44. Poehling S, Pippig SD, Hellerbrand K, et al. Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006;77:1582–1590
  45. Feeley BT, Conduah AH, Sugiyama O, et al. In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res. 2006;24:1709–1721
  46. Virk MS, Conduah A, Park SH, et al. Influence of short-term adenoviral vector and prolonged lentiviral vector mediated bone morphogenetic protein-2 expression on the quality of bone repair in a rat femoral defect model. Bone. 2008;42:921–931
  47. Deasy BM, Huard J. Gene therapy and tissue engineering based on muscle-derived stem cells. Curr Opin Mol Ther. 2002;4:382–389
  48. Usas A, Ho AM, Cooper GM, et al. Bone regeneration mediated by BMP4-expressing muscle-derived stem cells is affected by delivery system. Tissues Eng Part A. 2009;2:285–293

PII: S1048-6666(09)00093-7

doi: 10.1053/j.oto.2009.07.003

Operative Techniques in Orthopaedics
Volume 19, Issue 2 , Pages 77-87 , April 2009

Article Tools

* Image Usage & Resolution